For the first time, scientists have used CRISPR technology to insert genes that allow immune cells to focus their attack on cancer cells, potentially leaving normal cells unharmed and increasing the effectiveness of immunotherapy.

Preclinical study uses nanoparticles to attach immune-activating molecule to tumors.